Phentermine and topiramate for the management of obesity: a review

References

• Ahluwalia IB Mack KA Mokdad A Report from the CDC. Changes in selected chronic disease-related risks and health conditions for nonpregnant women 18–44 years old BRFSS J Womens Health (Larchmt) 6 2005 14 5 382 386 15989409
   PubMed Web of Science ®Google Scholar
• Ford ES Mokdad AH Giles WH Galuska DA Serdula MK Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors Obes Res 1 2005 13 1 118 122 15761170
   PubMedGoogle Scholar
• Ford ES Mokdad AH Epidemiology of obesity in the Western Hemisphere J Clin Endocrinol Metab 11 2008 93 11 Suppl 1 S1 S8 18987267
   PubMed Web of Science ®Google Scholar
• Ford ES Zhao G Li C Pearson WS Mokdad AH Trends in obesity and abdominal obesity among hypertensive and nonhypertensive adults in the United States Am J Hypertens 10 2008 21 10 1124 1128 18772861
   PubMed Web of Science ®Google Scholar
• Thorpe KE Philyaw M The medicalization of chronic disease and costs Annu Rev Public Health 4 2012 33 409 423 22224894
   PubMed Web of Science ®Google Scholar
• Khan A Raza S Khan Y Current updates in the medical management of obesity Recent Pat Endocr Metab Immune Drug Discov 5 2012 6 2 117 128 22435392
   PubMedGoogle Scholar
• Plourde G Prud’homme D Managing obesity in adults in primary care Cmaj 6 12 2012 184 9 1039 1044 22586330
   PubMed Web of Science ®Google Scholar
• Robinson GA Geier M Rizzolo D Sedrak M Childhood obesity: complications, prevention strategies, treatment Jaapa 12 2011 24 12 58 63 22315918
   PubMedGoogle Scholar
• 17 Lakshman R Elks CE Ong KK Childhood obesity Circulation 10 2 2012 126 14 1770 1779 23027812
   PubMed Web of Science ®Google Scholar
• Holterman MJ Le Holterman AX Browne AF Pediatric obesity Surg Clin North Am 6 2012 92 3 559 582 viii 22595709
   PubMed Web of Science ®Google Scholar
• Li Z Heber D Sarcopenic obesity in the elderly and strategies for weight management Nutr Rev 1 2012 70 1 57 64 22221216
   PubMed Web of Science ®Google Scholar
• Donini LM Savina C Gennaro E A systematic review of the literature concerning the relationship between obesity and mortality in the elderly J Nutr Health Aging 1 2012 16 1 89 98 22238007
   PubMed Web of Science ®Google Scholar
• Mathus-Vliegen EM Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline Obes Facts 2012 5 3 460 483 22797374
   PubMed Web of Science ®Google Scholar
• Witkamp RF Current and future drug targets in weight management Pharm Res 8 2011 28 8 1792 1818 21181547
   PubMed Web of Science ®Google Scholar
• Shekelle PG Morton SC Maglione M Pharmacological and surgical treatment of obesity Evid Rep Technol Assess (Summ) 7 2004 103 1 6 15526396
   PubMedGoogle Scholar
• Norris SL Zhang X Avenell A Gregg E Schmid CH Lau J Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus Cochrane Database Syst Rev 2005 1 CD004096 15674929
   PubMedGoogle Scholar
• Chugh PK Sharma S Recent advances in the pathophysiology and pharmacological treatment of obesity J Clin Pharm Ther 10 2012 37 5 525 535 22462645
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL Piccenna L McNeil JJ Pharmacotherapies for obesity: past, current, and future therapies J Obes 2011 2011 179674 21197148
   PubMedGoogle Scholar
• Derosa G Maffioli P Anti-obesity drugs: a review about their effects and their safety Expert Opin Drug Saf 5 2012 11 3 459 471 22439841
   PubMed Web of Science ®Google Scholar
• Kushner RF Manzano H Obesity pharmacology: past, present, and future Curr Opin Gastroenterol 3 2002 18 2 213 220 17033290
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL Proietto J McNeil JJ Pharmacotherapy for obesity Drugs 2005 65 10 1391 1418 15977970
   PubMed Web of Science ®Google Scholar
• Li Z Maglione M Tu W Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 4 5 2005 142 7 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Halford JC Boyland EJ Blundell JE Kirkham TC Harrold JA Pharmacological management of appetite expression in obesity Nat Rev Endocrinol 5 2010 6 5 255 269 20234354
   PubMed Web of Science ®Google Scholar
• Greenway FL Bray GA Combination drugs for treating obesity Curr Diab Rep 4 2010 10 2 108 115 20425569
   PubMed Web of Science ®Google Scholar
• Johnson AM Two new drugs approved for obesity S D Med 9 2012 65 9 356 357 23066610
   PubMedGoogle Scholar
• Taylor AA Ragbir S Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension Patient Prefer Adherence 2012 6 555 563 22927748
   PubMed Web of Science ®Google Scholar
• Taddei S Fixed-dose combination therapy in hypertension: pros High Blood Press Cardiovasc Prev 6 1 2012 19 2 55 57 22867090
   PubMedGoogle Scholar
• Han S Iglay K Davies MJ Zhang Q Radican L Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis Curr Med Res Opin 6 2012 28 6 969 977 22494018
   PubMed Web of Science ®Google Scholar
• Garcia-Donaire JA Ruilope LM Multiple action fixed combination. Present or future? Fundam Clin Pharmacol 2 24 1 37 42 20002751
   PubMed Web of Science ®Google Scholar
• Gerbino PP Shoheiber O Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents Am J Health Syst Pharm 6 2007 64 12 1279 1283 17563050
   PubMed Web of Science ®Google Scholar
• Bangalore S Shahane A Parkar S Messerli FH Compliance and fixed-dose combination therapy Curr Hypertens Rep 6 2007 9 3 184 189 17519122
   PubMed Web of Science ®Google Scholar
• Sanz G Fuster V Polypill and global cardiovascular health strategies Semin Thorac Cardiovasc Surg Spring 2011 23 1 24 29 21807295
   PubMedGoogle Scholar
• Garcia-Donaire JA Ruilope LM Multiple action fixed combination. Present or future? Fundam Clin Pharmacol 2 2010 24 1 37 42 20002751
   PubMed Web of Science ®Google Scholar
• Klonoff DC Greenway F Drugs in the pipeline for the obesity market J Diabetes Sci Technol 9 2008 2 5 913 918 19885278
   PubMedGoogle Scholar
• Atkinson RL Blank RC Schumacher D Dhurandhar NV Ritch DL Long-term drug treatment of obesity in a private practice setting Obes Res 11 1997 5 6 578 586 9449143
   PubMedGoogle Scholar
• Spitz AF Schumacher D Blank RC Dhurandhar NV Atkinson RL Long-term pharmacologic treatment of morbid obesity in a community practice Endocr Pract Sep-Oct 1997 3 5 269 275 15251779
   PubMedGoogle Scholar
• Astrup A Breum L Toubro S Hein P Quaade F The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial Int J Obes Relat Metab Disord 4 1992 16 4 269 277 1318281
   PubMed Web of Science ®Google Scholar
• Weintraub M Sundaresan PR Schuster B Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise Clin Pharmacol Ther 5 1992 51 5 595 601 1587073
   PubMed Web of Science ®Google Scholar
• Weintraub M Sundaresan PR Madan M Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo Clin Pharmacol Ther 5 1992 51 5 586 594 1587072
   PubMed Web of Science ®Google Scholar
• Astrup A Toubro S Cannon S Hein P Madsen J Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study Metabolism 3 1991 40 3 323 329 2000046
   PubMed Web of Science ®Google Scholar
• Mercer SL ACS Chemical Neuroscience Molecule Spotlight on Contrave ACS Chem Neurosci 9 21 2011 2 9 484 486 22860172
   PubMed Web of Science ®Google Scholar
• Ornellas T Chavez B Naltrexone SR/bupropion SR (contrave): a new approach to weight loss in obese adults P T 5 2011 36 5 255 262 21785538
   PubMedGoogle Scholar
• Greenway FL Dunayevich E Tollefson G Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo J Clin Endocrinol Metab 12 2009 94 12 4898 4906 19846734
   PubMed Web of Science ®Google Scholar
• Greenway FL Whitehouse MJ Guttadauria M Rational design of a combination medication for the treatment of obesity Obesity (Silver Spring) 1 2009 17 1 30 39 18997675
   PubMed Web of Science ®Google Scholar
• Gadde KM Allison DB Ryan DH Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 4 16 2011 377 9774 1341 1352 21481449
   PubMed Web of Science ®Google Scholar
• Garvey WT Ryan DH Look M Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 2 2012 95 2 297 308 22158731
   PubMed Web of Science ®Google Scholar
• Allison DB Gadde KM Garvey WT Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2 2012 20 2 330 342 22051941
   PubMed Web of Science ®Google Scholar
• Colman E Anorectics on trial: a half century of federal regulation of prescription appetite suppressants Ann Intern Med 9 6 2005 143 5 380 385 16144896
   PubMed Web of Science ®Google Scholar
• Colman E Golden J Roberts M Egan A Weaver J Rosebraugh C The FDA’s assessment of two drugs for chronic weight management N Engl J Med 10 25 2012 367 17 1577 1579 23050510
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Greenway FL A study of abrupt phentermine cessation in patients in a weight management program Am J Ther 7 2011 18 4 292 299 20592662
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Rothman RB Greenway FL How physician obesity specialists use drugs to treat obesity Obesity (Silver Spring) 9 2009 17 9 1730 1735 19300434
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Greenway FL Westman EC Gupta AK Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity Obesity (Silver Spring) 12 2011 19 12 2351 2360 21527891
   PubMed Web of Science ®Google Scholar
• Lexicomp http://online.lexi.com.ezproxy.xula.edu/lco/action/home Lexicomp Online Web Site Accessed Nov 2012
   Google Scholar
• Bray GA Drug insight: appetite suppressants Nat Clin Pract Gastroenterol Hepatol 2 2005 2 2 89 95 16265126
   PubMedGoogle Scholar
• Adipex-P^® [package insert] Sellersville, PA Teva Pharmaceuticals, USA 2012
   Google Scholar
• Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon? Prescrire Int 9 21 130 209
   Google Scholar
• Munro JF MacCuish AC Wilson EM Duncan LJ Comparison of continuous and intermittent anorectic therapy in obesity Br Med J 2 10 1968 1 5588 352 354 15508204
   PubMed Web of Science ®Google Scholar
• Rothman RB Hendricks EJ Phentermine cardiovascular safety Am J Emerg Med 10 2009 27 8 1010 1013 19857423
   PubMed Web of Science ®Google Scholar
• Makoundou V Golay A Drug control of appetite Rev Med Suisse 1 12 2011 7 277 57 60 21309176
   PubMedGoogle Scholar
• Uwaifo GI Melcescu E McDonald A Koch CA A case of profound weight loss secondary to use of phentermine J Miss State Med Assoc 12 2009 50 12 407 415 20806811
   PubMedGoogle Scholar
• Tonstad S Tykarski A Weissgarten J Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension Am J Cardiol 7 15 2005 96 2 243 251 16018851
   PubMed Web of Science ®Google Scholar
• Shank RP Gardocki JF Vaught JL Topiramate: preclinical evaluation of structurally novel anticonvulsant Epilepsia Mar-Apr 1994 35 2 450 460 8156972
   PubMed Web of Science ®Google Scholar
• Shank RP Gardocki JF Streeter AJ Maryanoff BE An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action Epilepsia 2000 41 Suppl 1 S3 S9 10768292
   PubMed Web of Science ®Google Scholar
• Shank RP Maryanoff BE Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate CNS Neurosci Ther Summer 2008 14 2 120 142 18482025
   PubMed Web of Science ®Google Scholar
• NCBI Topiramate; Compound summary CID 5284627 Pub Chem compound [website] Accessed Dec 2012
   Google Scholar
• NCBI Topamax (TN)-Substance summary SID 7847603 [Website] Accessed Dec 2012
   Google Scholar
• Storey JR Calder CS Hart DE Potter DL Topiramate in migraine prevention: a double-blind, placebo-controlled study Headache Nov-Dec 2001 41 10 968 975 11903524
   PubMed Web of Science ®Google Scholar
• Chengappa KN Rathore D Levine J Topiramate as add-on treatment for patients with bipolar mania Bipolar Disord 9 1999 1 1 42 53 11256656
   PubMedGoogle Scholar
• Bray GA Hollander P Klein S A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 6 2003 11 6 722 733 12805393
   PubMedGoogle Scholar
• Lexicomp Topiramate; Drug information Uptodate^® Available at: http://www.uptodate.com Accessed Dec 2012
   Google Scholar
• Ben-Menachem E Axelsen M Johanson EH Stagge A Smith U Predictors of weight loss in adults with topiramate-treated epilepsy Obes Res 4 2003 11 4 556 562 12690085
   PubMedGoogle Scholar
• Wilding J Van Gaal L Rissanen A Vercruysse F Fitchet M A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects Int J Obes Relat Metab Disord 11 2004 28 11 1399 1410 15486569
   PubMed Web of Science ®Google Scholar
• Astrup A Toubro S Topiramate: a new potential pharmacological treatment for obesity Obes Res 12 2004 12 Suppl 167S 173S 15687413
   PubMedGoogle Scholar
• Bays HE Gadde KM Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity Drugs Today (Barc) 12 2011 47 12 903 914 22348915
   PubMed Web of Science ®Google Scholar
• Bays H Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease Expert Rev Cardiovasc Ther 12 8 12 1777 1801 20707765
   PubMedGoogle Scholar
• Cameron F Whiteside G McKeage K Phentermine and topiramate extended release (qsymia): first global approval Drugs 10 22 2012 72 15 2033 2042 23039320
   PubMed Web of Science ®Google Scholar
• Malgarini RB Pimpinella G Phentermine plus topiramate in the treatment of obesity Lancet 7 9 2011 378 9786 125 126 author reply 126–127 21742167
   PubMed Web of Science ®Google Scholar
• Mercer SL ACS chemical neuroscience molecule spotlight on Qnexa ACS Chem Neurosci 4 20 2011 2 4 183 184 22778866
   PubMed Web of Science ®Google Scholar
• Shah K Villareal DT Combination treatment to CONQUER obesity? Lancet 4 16 2011 377 9774 1295 1297 21497686
   PubMed Web of Science ®Google Scholar
• Qsymia [prescribing information] Mountain view, CA Vivus 2012
   Google Scholar
• Aronne LJ Peterson C Troupin B Weight loss with V1-0521 (phentermine/controlled release topiramate) stops progression towards type 2 diabetes in obese non-diabetic subjects Poster PO.22 presented at: 2010 Obesity Society meeting and the abstract included in Obesity Facts
   Google Scholar
• Ryan DH Peterson C Troupin B Weight loss at 6 months with V1-0521 (PEN/TPM combination) treatment Paper presented at the 69th Annual Scientific Sessions of the American Diabetes Association June 5, 2009
   Google Scholar
• VIVUS I VIVUS Reports Topline Findings from FORTRESS [media release on the Internet] 12 21 2011 Available at http://ir.vivus.com/releasedetail.cfm?ReleaseID=634920
   Google Scholar
• Barter PJ Caulfield M Eriksson M Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 11 22 2007 357 21 2109 2122 17984165
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Topol EJ Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus JAMA 11 23 2005 294 20 2581 2586 16239637
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Intern Med 7 26 2010 170 14 1191 1201 20656674
   PubMed Web of Science ®Google Scholar